The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
Publication|Videos|May 30, 2024
Recent Pharma Trends, EU Annex 1, and More with Syntegon
Author(s)Syntegon Pharma Technology
At a recent INTERPHEX conference, Laura Moody (Director of Product Management, Pharma North America, Syntegon) shared some insights into current trends in the pharmaceutical industry, including the EU Annex 1.
Between bigger commitments to sustainability, updated regulatory requirements, and increasingly innovative equipment, the pharmaceutical industry is undergoing a great deal of change. To learn more, Pharmaceutical Technology spoke with Laura Moody, Director of Product Management for Pharma North America at Syntegon. Watch this video to learn more about:
- The current landscape of the pharmaceutical industry, including current trends;
- How the EU Annex 1 affects pharmaceutical companies;
- How Syntegon supports pharmaceutical companies in drug making processes.
Related to this article
Jaenisch, Muraru, and Pandey discuss how regulators will audit pharma against its own AI policies and ways QA and regulatory teams can build defensible, inspection-ready AI practices.
Impurity deficiencies in submissions are remarkably consistent. Subathra Ramamoorthy, Veranova, explains how to catch them before agency filing.
USP’s Sheehan and Liu talk at AAPS PharmSci 360 abou getting novel excipients past the monograph hurdle through early engagement with FDA.
CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
The business case for regulated AI turns on the cost of producing an outcome that the quality system can accept.
In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.
Trending on Pharmaceutical Technology
1
Improving Oral Peptide Delivery Through Structural Modifications
2
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
3
Regulatory Roundup—October 2026: FDA Advances Rare Disease Development and Transparency Efforts
4
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
5